Enhanced survival for patients with hepatocellular carcinoma
A new study has unveiled a promising adjuvant therapy regimen that significantly improves patient outcomes…
A new study has unveiled a promising adjuvant therapy regimen that significantly improves patient outcomes…
“To date, the HIMALAYA study is one of the largest phase III studies conducted with…
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo…
New treatment options for people with advanced or unresectable hepatocellular carcinoma (HCC) may now be…
In the journal Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for…
Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival…